leukaemia

Pleco Therapeutics BV has raised €17.3 million in its Series A financing round, which will be used to complete the development of its Plecoid Product, PTX-061, to improve the effectiveness of chemotherapy in patients with acute myeloid leukaemia (AML). The investments include €3.6 million committed by Oost NL and a select number of private investors, […]

The European Commission (EC) has approved orphan drug Scemblix (asciminib), providing a new treatment option for patients who are intolerant or resistant to tyrosine kinase inhibitors (TKIs). It is approved to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase who have been previously treated with two or more TKI therapies. Scemblix is the […]

This poster by Levitas Bio provides a useful guide for leukaemia researchers wanting to use scRNAseq and analysis to uncover new data points. Download the Poster to discover more about: scRNAseq and analysis with enriched, purified cells leads to better data, often uncovering data points that may be obscured by dead cells and debris Engraftment in […]

Biopharmaceutical company Nurix Therapeutics has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Phase 1 trial of its lead drug candidate targeting relapsed or refractory B-cell malignancies  The company’s lead candidate, NX-2127, is an orally administered degrader of Bruton’s tyrosine kinase (BTK) with immunomodulatory activity. Nurix had initially launched NX-2127 […]